Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. ALL progresses rapidly and is typically fatal within weeks or months if left untreated. ALL is typically treated initially with chemotherapy aimed at bringing about remission but can be further treated with chemotherapy over a longer period of time. Treatment usually also includes intrathecal …
Approximately 8000 patients per year with multiple myeloma (MM) receive a stem cell transplant in the United States. Ten years ago, the number of transplants were about 5,550. MM is a cancer that affects plasma cells in the bone marrow, causing them to divide rapidly. While melphalan is currently the standard of care, it has …
beta thallasemia
Sickle cell anemia is a serious genetic disease. It is associated with significant pain and often results in stroke, severe infections, progressive organ damage and death, often at a young age. Approximately 25% of all sickle cell anemia patients suffer a stroke prior to age 45. This disease affects about one out of every 365 …
Certain tumors, e.g., breast cancer, malignant melanomas, and multiple myeloma in addition to acute leukemias often spread to the central nervous system. Aside from radiation, which can only be used once, there is no preferred treatment for such tumor involvement. Bulanta, which has an excellent anti- tumor spectrum, can be expected to be effective in …
Beta Thalassemia is a genetic disorder characterized by abnormal hemoglobin production or a shortage of healthy red blood cells. It occurs in 280 million people with at least 439,000 severe cases. This disease is most prevalent among individuals of Mediterranean, South Asia and Middle Eastern descent. Severe Beta thalassemia affects about 1,300 people in the United States. Stem …
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin a risus fermentum mi venenatis finibus. Suspendisse eget volutpat tortor, eget lobortis eros. Vestibulum lorem massa, volutpat a congue nec, posuere at odio. Donec sed purus luctus, fermentum est in, convallis justo. Nulla tempus arcu eu porttitor scelerisque. Integer in pharetra ligula. Donec et venenatis nisl. …
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin a risus fermentum mi venenatis finibus. Suspendisse eget volutpat tortor, eget lobortis eros. Vestibulum lorem massa, volutpat a congue nec, posuere at odio. Donec sed purus luctus, fermentum est in, convallis justo. Nulla tempus arcu eu porttitor scelerisque. Integer in pharetra ligula. Donec et venenatis nisl. …
